Global Gonorrhea Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Gonorrhea Therapeutics Market Growth (Status and Outlook) 2023-2029

Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.

LPI (LP Information)' newest research report, the “Gonorrhea Therapeutics Industry Forecast” looks at past sales and reviews total world Gonorrhea Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Gonorrhea Therapeutics sales for 2023 through 2029. With Gonorrhea Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gonorrhea Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Gonorrhea Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gonorrhea Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gonorrhea Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gonorrhea Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gonorrhea Therapeutics.

The global Gonorrhea Therapeutics market size is projected to grow from US$ 1029.5 million in 2022 to US$ 1368.4 million in 2029; it is expected to grow at a CAGR of 4.1% from 2023 to 2029.

The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea. Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.

This report presents a comprehensive overview, market shares, and growth opportunities of Gonorrhea Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Monotherapy
Dual Therapy

Segmentation by application
Clinics
Hospitals
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bharat Pharmaceuticals
GlaxoSmithKline
Merck
Pfizer
Alopexx Pharmaceuticals
AstraZeneca
Debiopharm Group
Melinta Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.